MGEN News and Press, Miragen Therapeutics Inc. From 03/13/19

Cobomarsen tested in clinical trials for three different types of blood cancers Multiple clinical sites open and actively recruiting in the global Phase 2 SOLAR clinical trial of cobomarsen in CTCL Data from four clinical trials of three product candidates expected to be released i...

BOULDER, Colo., March 06, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer...

BOULDER, Colo., Feb. 20, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Wednesday, March 13, at 4:30 p.m. ET to discuss its fina...

Gainers: Organogenesis Holdings ( ORGO ) +57% . Rand Capital (NASDAQ: RAND ) +32% . PHI (NASDAQ: PHII ) +26% . ClearOne (NASDAQ: CLRO ) +23% . Bristow Group (NYSE: BRS ) +20% . Digital Ally (NASDAQ: DGLY ) +17% . SITO Mobile (NASDAQ: SITO ) +16% . Achaogen (NASDAQ: AKAO ) +16% . C...

The following slide deck was published by Miragen Therapeutics, Inc. in conjunction with this Read more ...